Repurposing FDA-Approved Drugs to Modulate CRISPR DNA Repair Pathways

Study Background and Research Question

DNA double-strand breaks (DSBs) are a fundamental threat to genome integrity, occurring both spontaneously and in response to exogenous insults such as ionizing radiation and chemotherapeutic agents (source: paper). The advent of CRISPR-Cas9 technology has enabled targeted induction of DSBs at predetermined genomic loci, revolutionizing gene editing for disease modeling, therapeutic intervention, and functional genomics. However, the outcomes of targeted DSB repair are governed by the relative activity of endogenous repair pathways, primarily non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR). Each pathway introduces distinct mutation signatures—ranging from small indels to precise sequence changes—impacting the fidelity and outcome of genome editing experiments. A persistent challenge in CRISPR applications is the ability to direct repair toward a desired pathway to achieve precise edits or specific gene disruptions. Thus, the central research question addressed in the referenced study is: Can clinically approved drugs be repurposed to modulate DSB repair pathway choice, thereby refining CRISPR genome editing outcomes and enabling targeted synthetic lethality in cancer cells?

Key Innovation from the Reference Study

The authors present a large-scale, unbiased screen of over 7,000 FDA-approved drugs and pharmacologically active compounds to assess their impact on DSB repair pathway choice in human induced pluripotent stem cells (hiPSCs) engineered with CRISPR-Cas9 (source: paper). This approach leverages the clinical safety profiles of existing drugs, accelerating the translational potential for genome editing and precision medicine applications. Notably, the study not only identifies compounds that either inhibit or enhance specific pathways (NHEJ, MMEJ, HDR), but also uncovers drug-induced synthetic lethality in the context of pathway inhibition. Furthermore, it reveals previously unappreciated roles for proteins such as ESR2 and AOX1 in modulating the activity of key DNA repair factors (e.g., ATM, 53BP1), broadening the mechanistic understanding of repair regulation.

Methods and Experimental Design Insights

The experimental workflow was meticulously designed to allow high-throughput screening of drug effects on DSB repair outcomes (source: paper):

• Human iPSCs (409B2 line) expressing a doxycycline-inducible Cas9 (iCRISPR) were employed as the cellular platform.
• Cells were exposed to individual drugs during CRISPR-mediated editing of the FRMD7 genomic locus.
• After recovery, cell viability was quantified using a resazurin fluorescence assay to assess cytotoxicity and synthetic lethality.
• Genomic DNA was extracted and subjected to high-throughput Illumina sequencing to quantify repair outcomes—specifically, the frequencies of HDR, NHEJ (indels <2 bp microhomology), and MMEJ (deletions ≥2 bp microhomology).
• Each drug was tested in a single replicate (n = 7240 conditions) to maximize the breadth of the screen, recognizing the trade-off of limited replication per condition (source: paper).

The screen also incorporated genetic perturbation experiments, such as silencing ESR2 and AOX1, to dissect the regulatory network influencing repair pathway choice.

Core Findings and Why They Matter

The screen yielded several notable discoveries:

• Repair Pathway Modulators: Multiple drugs were identified that selectively enhance or suppress NHEJ, MMEJ, or HDR outcomes. For example, NHEJ inhibitors (e.g., DNA-PKcs inhibitors) shifted repair toward HDR or MMEJ, while HDR inhibitors (e.g., RAD51 inhibitors) suppressed precise editing (source: paper).
• Pathway Synergy: Silencing of ESR2, when combined with NHEJ inhibition, synergistically increased HDR efficiency by an average of 4.6-fold—demonstrating the potential of combinatorial approaches to boost precise editing (source: paper).
• Synthetic Lethality: Several drugs induced selective lethality in cells where NHEJ or HDR pathways were pharmacologically or genetically inhibited. This finding opens avenues for precision oncology, where exploiting repair vulnerabilities can selectively target cancer cells (source: paper).
• Gene Editing Fidelity: The ability to pharmacologically bias DSB repair outcomes enables improved predictability and efficiency in CRISPR-based disease models and therapeutic strategies, including template-based gene correction and CAR-T engineering (source: paper).

These findings are directly relevant for researchers seeking to optimize gene editing outcomes, enhance disease modeling, or develop precision therapies based on synthetic lethality.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on small molecule modulation of DNA repair and calcium signaling in genome editing workflows:

• Dantrolene Sodium Salt: Mechanistic Power and Translation... explores how ryanodine receptor antagonists such as dantrolene sodium salt enable advanced control of intracellular calcium, with direct implications for disease modeling and CRISPR workflows. This resource provides in-depth mechanistic context on calmodulin-dependent RyR inhibition and links calcium signaling modulation to DNA repair pathway choice (source: workflow_recommendation).
• Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagonist Workflows details validated protocols for using dantrolene sodium salt in cell-based assays, emphasizing its role as a reproducible ryanodine receptor antagonist in genome editing and synthetic lethality models (source: workflow_recommendation).
• Targeting Ryanodine Receptor Signaling for Precision Modulation of DNA Repair further synthesizes evidence on the intersection of calcium signaling and DSB repair, highlighting the translational opportunities afforded by compounds like dantrolene sodium salt in gene editing and cancer models (source: workflow_recommendation).

While the reference study focuses on the identification of repair pathway modulators via drug repurposing, these internal articles elaborate on how specific calcium modulators can be integrated into experimental designs to influence repair outcomes and cellular phenotypes, particularly in neurodegenerative and ischemia research contexts.

Limitations and Transferability

Several caveats must be considered when interpreting the study results:

• Replication and Validation: The screen used single replicates for each drug condition, prioritizing breadth over depth. Follow-up studies are needed to confirm hits and establish dose-response relationships (source: paper).
• Cell Type Specificity: All experiments were performed in a single hiPSC line; repair pathway dominance and drug responses may vary in other cell types or primary cells (source: paper).
• In Vivo Translation: While the use of clinically approved drugs enhances translational potential, the pharmacodynamics and off-target effects in whole-organism settings remain to be rigorously evaluated (source: paper).
• Mechanistic Elucidation: For many screened compounds, the precise molecular targets underlying modulation of repair pathways are yet to be elucidated, necessitating further mechanistic studies (source: paper).

Despite these limitations, the study provides a valuable resource for prioritizing compounds for further functional validation in genome editing, synthetic lethality, and precision medicine research.

Protocol Parameters

• assay | Resazurin cell viability | 2–4 h post-treatment | High-throughput cytotoxicity screening | Enables rapid identification of synthetic lethal interactions | paper
• assay | Illumina sequencing (amplicon) | ~200 bp target region | Quantitative analysis of repair pathway outcomes (NHEJ, MMEJ, HDR) | High-resolution mapping of mutational signatures | paper
• compound screening | Single replicate per drug | hiPSC model | Maximizes screening breadth, but limits statistical power | paper
• calcium signaling modulation | Dantrolene sodium salt: 0.1–10 μM | Mouse cardiomyocytes, hiPSCs | Calmodulin-dependent RyR inhibition to modulate calcium release and downstream DNA repair signaling | workflow_recommendation
• storage | Dantrolene sodium salt: room temperature (solid) | All workflows | Preserves compound stability and activity for short-term use | product_spec

Research Support Resources

To support DNA repair pathway research, especially in the context of calcium signaling modulation and genome editing, researchers may consider incorporating Dantrolene, sodium salt (SKU B6329) as a high-purity ryanodine receptor antagonist. This compound, available from APExBIO, has demonstrated efficacy in modulating intracellular calcium release and influencing cellular responses relevant to DNA repair, neurodegenerative disease, and ischemia research (source: workflow_recommendation). For detailed protocols and assay recommendations, consult the referenced internal articles and product documentation.